文献速递类风湿关节炎

非戈替尼对3期FINCH研究中疼痛控制的影响

Impact of filgotinib on pain control in the phase 3 FINCH studies.
PubMed 文献 · RMD Open · 2024-03-12

本文为FINCH 1-3研究的事后分析,评估非戈替尼对类风湿关节炎患者疼痛控制的影响及其与其他疗效指标的关系。结果显示非戈替尼从第2周起减轻疼痛并持续至研究结束;在FINCH 1中,非戈替尼200mg组达到VAS疼痛≤20mm且DAS28-CRP缓解的患者比例高于100mg组、阿达木单抗组和安慰剂组。

要点

  • 非戈替尼从第2周起减轻疼痛,且缓解持续至研究结束。
  • FINCH 1第24周,非戈替尼200mg组VAS疼痛≤20mm且DAS28-CRP缓解比例为35.8%,高于100mg组25.0%、阿达木单抗组24.6%和安慰剂组11.6%。
  • FINCH 1中非戈替尼100mg的疼痛改善与阿达木单抗相似,200mg改善更明显。

核心结论

  • 在所有研究的类风湿关节炎人群中,疼痛从第2周起改善并持续存在。
  • FINCH 1中非戈替尼100mg的疼痛改善与阿达木单抗相似,而非戈替尼200mg带来更大疼痛改善及更高比例的残余疼痛≤10或≤20mm且符合DAS28-CRP缓解标准的患者。

研究设计与样本

  • FINCH 1-3(NCT02889796、NCT02873936和NCT02886728)研究的事后分析。
  • 评估指标包括100mm视觉模拟量表(VAS)上残余疼痛应答≤10mm和≤20mm,以及达到VAS疼痛应答同时符合DAS28-CRP或CDAI缓解或低疾病活动度的患者比例。

主要发现

  • 各研究中非戈替尼从第2周起减轻疼痛,应答持续整个研究期间。
  • FINCH 1第24周,非戈替尼200mg组、非戈替尼100mg组、阿达木单抗组和安慰剂组(均联合甲氨蝶呤)达到VAS疼痛≤20mm且DAS28-CRP缓解的比例分别为35.8%、25.0%、24.6%和11.6%。
  • FINCH 1第24周,上述四组达到VAS疼痛≤10mm且DAS28-CRP缓解的比例分别为26.3%、17.9%、17.2%和7.6%。
  • CDAI缓解方面观察到相似模式;VAS疼痛≤10或≤20mm的时间在非戈替尼200mg组最长,阿达木单抗与非戈替尼100mg之间相当。
  • FINCH 2和FINCH 3中非戈替尼也报告了相似结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This post hoc analysis of the FINCH 1-3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA). METHODS: Assessments included: residual pain responses of ≤10 and ≤20 mm on a 100 mm visual analogue scale (VAS); the proportion of patients who achieved VAS pain responses in addition to remission or low disease activity by Disease Activity Score-28 with C-reactive protein (DAS28-CRP) or Clinical Disease Activity Index (CDAI) criteria. RESULTS: Across studies, filgotinib reduced pain from week 2, with responses sustained throughout the studies. In FINCH 1, at week 24, 35.8%, 25.0%, 24.6% and 11.6% of patients in the filgotinib 200 mg, filgotinib 100 mg, adalimumab and placebo arms (each plus methotrexate) achieved VAS pain ≤20 mm in addition to DAS28-CRP remission; 26.3%, 17.9%, 17.2% and 7.6% achieved VAS pain ≤10 mm in addition to DAS28-CRP remission. A similar pattern was seen for CDAI remission. Time during which VAS pain was ≤10 or ≤20 mm was longest with filgotinib 200 mg and comparable between adalimumab and filgotinib 100 mg. Similar findings were reported for filgotinib in FINCH 2 and 3. CONCLUSION: In all RA populations studied, pain improvements occurred from week 2 and were sustained over time. In FINCH 1, filgotinib 100 mg provided similar pain amelioration to adalimumab, whereas filgotinib 200 mg resulted in greater pain improvement and higher proportion of patients with residual pain ≤10 or ≤20 mm and meeting DAS28-CRP remission criteria.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Kavanaugh A, Nash P, et al. Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD Open. 2024. PMID: 38479751. doi:10.1136/rmdopen-2023-003839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。